読み込み中
NASDAQHealthcareBiotechnology
最新データ
$4.88
−$0.43 · -8.10%
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
終値時点
$4.88
−$0.43 · -8.10%
時間外
$5.01
+$0.13 · +2.66%
10月12日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
日中レンジ
現在 $4.88
52週レンジ
現在 $4.88
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
53
まちまち
リスク
69
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
日中レンジ
現在 $4.88
52週レンジ
現在 $4.88
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上高 | — | — | — | 2.6万 USD |
| 売上原価 | — | — | — | 2.16万 USD |
| 粗利益 | — | — | — | 4429 USD |
| 研究開発 | 298.59万 USD | — | — | — |
| 販売・一般管理 | 125.32万 USD | 29.04万 USD | 1.93万 USD | 2.47万 USD |
| 営業費用 | 423.91万 USD | 36.51万 USD | 1.93万 USD | 2.47万 USD |
| 支払利息 | 8537 USD | — | — | — |
| 減価償却費と償却費 | 7.94万 USD | — | 1815 USD | 2.12万 USD |
| 営業利益 | −423.91万 USD | −36.51万 USD | −1.93万 USD | −2.02万 USD |
| 純利益 | −422.51万 USD | −36.15万 USD | −1.92万 USD | −2.02万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
